Hutchmed (HCM) said Thursday it completed enrollment for a phase 2 trial in China evaluating fanregratinib in certain patients with intrahepatic cholangiocarcinoma (IHCC), a type of primary bile duct cancer.
The company said the single-arm trial enrolled 87 IHCC patients with fibroblast growth factor receptor 2 fusion/rearrangement, and will assess the drug's efficacy and safety, with the primary endpoint of measuring objective response rate.
Hutchmed expects topline results by late 2025, which could support a new drug application in China if positive, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.